- ThermoGenesis (KOOL) surges 32% after the company reported, along with its partner TotipotentRX, statistically significant results in five key areas in a Phase Ib trial of the latter's CLIRST stem-cell therapy for treating critical limb ischemia.
- The study comprised 17 patients and achieved its primary safety and secondary efficacy endpoints at 12 months.
- The areas that were assessed included survival rates that didn't require major amputations, a fall in resting and walking pain, improved walking distance and open wound healing.
- Critical limb ischemia is a severe blockage in the arteries in the lower extremities. (PR)
ThermoGenesis jumps following trial results
Jan 21 2014, 09:34 ET